James F Sanchez
Overview
Explore the profile of James F Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Aldoss I, Zhang J, Pillai R, Shouse G, Sanchez J, Mei M, et al.
Br J Haematol
. 2019 Aug;
187(2):e45-e48.
PMID: 31441045
No abstract available.
22.
Zuro D, Vagge S, Broggi S, Agostinelli S, Takahashi Y, Brooks J, et al.
Radiother Oncol
. 2019 Aug;
141:275-282.
PMID: 31421913
Purpose: Total marrow irradiation (TMI) is a highly conformal treatment of the human skeleton structure requiring a high degree of precision and accuracy for treatment delivery. Although many centers worldwide...
23.
Aldoss I, Yang D, Pillai R, Sanchez J, Mei M, Aribi A, et al.
Am J Hematol
. 2019 Jul;
94(10):E253-E255.
PMID: 31259427
No abstract available.
24.
Buettner R, Morales C, Wu X, Sanchez J, Li H, Melstrom L, et al.
Mol Ther Oncolytics
. 2019 Jun;
14:149-158.
PMID: 31211245
The immunosuppressive agent leflunomide has been used in the treatment of over 300,000 patients with rheumatoid arthritis. Its active metabolite, teriflunomide (Ter), directly inhibits dihydroorotate dehydrogenase (DHODH), an enzyme involved...
25.
Buettner R, Morales C, Caserta E, Troadec E, Gunes E, Viola D, et al.
Blood Adv
. 2019 Apr;
3(7):1027-1032.
PMID: 30940637
No abstract available.
26.
Sahebi F, Garderet L, Kanate A, Eikema D, Knelange N, Alvelo O, et al.
Biol Blood Marrow Transplant
. 2018 Sep;
25(2):335-342.
PMID: 30243581
Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors has the potential for long-term disease control in a subset of high-risk patients with multiple myeloma (MM); however, the data...
27.
Aldoss I, Capelletti M, Park J, Pistofidis R, Pillai R, Stiller T, et al.
Leukemia
. 2018 Jul;
33(1):266-270.
PMID: 30026571
Multiple myeloma (MM) patients have an 11-fold increased risk of developing myeloid neoplasms compared to the general population; however, acute lymphoblastic leukemia (ALL) is rarely observed. Given that both MM...
28.
Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Remenyi P, et al.
Biol Blood Marrow Transplant
. 2018 Jan;
24(5):930-936.
PMID: 29339268
The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients...
29.
Caserta E, Chea J, Minnix M, Poku E, Viola D, Vonderfecht S, et al.
Blood
. 2018 Jan;
131(7):741-745.
PMID: 29301755
As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on...
30.
Brown C, Aguilar B, Starr R, Yang X, Chang W, Weng L, et al.
Mol Ther
. 2017 Nov;
26(1):31-44.
PMID: 29103912
T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen receptor (CAR) T ...